1. Muller, M., et al., *PTEN/MMAC1 mutations in prostate cancer.* Prostate Cancer Prostatic Dis, 2000. 3(S1): p. S32.
2. Feldman, B.J. and D. Feldman, *The development of androgen-independent prostate cancer.* Nat Rev Cancer, 2001. 1(1): p. 34-45.
3. Nelson, W.G., A.M. De Marzo, and W.B. Isaacs, *Prostate cancer.* N Engl J Med, 2003. 349(4): p. 366-81.
4. Truica, C.I., S. Byers, and E.P. Gelmann, *Beta-catenin affects androgen receptor transcriptional activity and ligand specificity.* Cancer Res, 2000. 60(17): p. 4709-13.
5. Chen, C.D., et al., *Molecular determinants of resistance to antiandrogen therapy.* Nat Med, 2004. 10(1): p. 33-39. Epub 2003 Dec 21.
6. Culig, Z., *Role of the androgen receptor axis in prostate cancer.* Urology, 2003. 62(5 Suppl 1): p. 21-6.
7. Giles, R.H., J.H. van Es, and H. Clevers, *Caught up in a Wnt storm: Wnt signaling in cancer.* Biochim Biophys Acta, 2003. 1653(1): p. 1-24.
8. Gounari, F., et al., *Stabilization of beta-catenin induces lesions reminiscent of prostatic intraepithelial neoplasia, but terminal squamous transdifferentiation of other secretory epithelia.* Oncogene, 2002. 21(26): p. 4099-107.
9. Mulholland, D.J., et al., *The androgen receptor can promote beta-catenin nuclear translocation independently of adenomatous polyposis coli.* J Biol Chem, 2002. 277(20): p. 17933-43.
10. Chesire, D.R., et al., *Ligand-dependent inhibition of beta-catenin/TCF signaling by androgen receptor.* Oncogene, 2002. 21(55): p. 8453-69.
11. Mulholland, D.J., et al., *Functional localization and competition between the androgen receptor and T-cell factor for nuclear beta-catenin: a means for inhibition of the Tcf signaling axis.* Oncogene, 2003. 22(36): p. 5602-13.
12. Bierie, B., et al., *Activation of beta-catenin in prostate epithelium induces hyperplasias and squamous transdifferentiation.* Oncogene, 2003. 22(25): p. 3875-87.
13. Chesire, D.R., et al., *Detection and analysis of beta-catenin mutations in prostate cancer.* Prostate, 2000. 45(4): p. 323-34.
14. Voeller, H.J., C.I. Truica, and E.P. Gelmann, *Beta-catenin mutations in human prostate cancer.* Cancer Res, 1998. 58(12): p. 2520-3.
15. Ghosh, P.M., et al., *Akt in prostate cancer: possible role in androgen-independence.* Curr Drug Metab, 2003. 4(6): p. 487-96.
16. Gao, N., et al., *Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer.* Biochem Biophys Res Commun, 2003. 310(4): p. 1124-32.
17. Vivanco, I. and C.L. Sawyers, *The phosphatidylinositol 3-Kinase AKT pathway in human cancer.* Nat Rev Cancer, 2002. 2(7): p. 489-501.
18. Graff, J.R., et al., *Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression.* J Biol Chem, 2000. 275(32): p. 24500-5.
19. Carson, J.P., G. Kulik, and M.J. Weber, *Antiapoptotic signaling in LNCaP prostate cancer cells: a survival signaling pathway independent of phosphatidylinositol 3'-kinase and Akt/protein kinase B.* Cancer Res, 1999. 59(7): p. 1449-53.
20. Murillo, H., et al., *Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state.* Endocrinology, 2001. 142(11): p. 4795-805.
21. Lin, H.K., et al., *Suppression versus induction of androgen receptor functions by the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer LNCaP cells with different passage numbers.* J Biol Chem, 2003. 278(51): p. 50902-7.
22. Gioeli, D., et al., *Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites.* J Biol Chem, 2002. 277(32): p. 29304-14.

P
C
0
4
0
0
9
2
4

23. Kotelevets, L., et al., *The lipid phosphatase activity of PTEN is critical for stabilizing intercellular junctions and reverting invasiveness.* J Cell Biol, 2001. **155**(7): p. 1129-35.
24. Persad, S., et al., *Tumor suppressor PTEN inhibits nuclear accumulation of beta-catenin and T cell/lymphoid enhancer factor 1-mediated transcriptional activation.* J Cell Biol, 2001. **153**(6): p. 1161-74.
25. Persad, S., et al., *Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells.* Proc Natl Acad Sci U S A, 2000. **97**(7): p. 3207-12.
26. Lin, J., et al., *The phosphatidylinositol 3'-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells.* Cancer Res, 1999. **59**(12): p. 2891-7.
27. Manin, M., et al., *Androgen receptor expression is regulated by the phosphoinositide 3-kinase/Akt pathway in normal and tumoral epithelial cells.* Biochem J, 2002. **366**(Pt 3): p. 729-36.
28. Yang, F., et al., *Linking beta-catenin to androgen-signaling pathway.* J Biol Chem, 2002. **277**(13): p. 11336-44.
29. Sharma, M., W.W. Chuang, and Z. Sun, *Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3beta inhibition and nuclear beta-catenin accumulation.* J Biol Chem, 2002. **277**(34): p. 30935-41.
30. Zhang, L., et al., *Interrogating androgen receptor function in recurrent prostate cancer.* Cancer Res, 2003. **63**(15): p. 4552-60.
31. Chesire, D.R., et al., *In vitro evidence for complex modes of nuclear beta-catenin signaling during prostate growth and tumorigenesis.* Oncogene, 2002. **21**(17): p. 2679-94.
32. Shtutman, M., et al., *The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway.* Proc Natl Acad Sci U S A, 1999. **96**(10): p. 5522-7.
33. Radu, A., et al., *PTEN induces cell cycle arrest by decreasing the level and nuclear localization of cyclin D1.* Mol Cell Biol, 2003. **23**(17): p. 6139-49.
34. Persad, S., et al., *Tumor suppressor PTEN inhibits nuclear accumulation of beta-catenin and T cell/lymphoid enhancer factor 1-mediated transcriptional activation.* J Cell Biol, 2001. **153**(6): p. 1161-74.
35. Maira, S.M., et al., *Carboxyl-terminal modulator protein (CTMP), a negative regulator of PKB/Akt and v-Akt at the plasma membrane.* Science, 2001. **294**(5541): p. 374-80.
36. El Gedaily, A., et al., *Discovery of new DNA amplification loci in prostate cancer by comparative genomic hybridization.* Prostate, 2001. **46**(3): p. 184-90.
37. Schonthal, A.H., *Role of PP2A in intracellular signal transduction pathways.* Front Biosci, 1998. **3**: p. D1262-73.
38. Remy, I. and S.W. Michnick, *Regulation of apoptosis by the ft1 protein, a new modulator of protein kinase b/akt.* Mol Cell Biol, 2004. **24**(4): p. 1493-504.
39. Wang, S., et al., *Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer.* Cancer Cell, 2003. **4**(3): p. 209-21.
40. Chesire, D.R., et al., *Detection and analysis of beta-catenin mutations in prostate cancer.* Prostate, 2000. **45**(4): p. 323-34.
41. Deocampo, N.D., H. Huang, and D.J. Tindall, *The role of PTEN in the progression and survival of prostate cancer.* Minerva Endocrinol, 2003. **28**(2): p. 145-53.
42. Chung, L.W., et al., *Human prostate cancer model: roles of growth factors and extracellular matrices.* J Cell Biochem Suppl, 1992. **16H**: p. 99-105.
43. Gingras, A.C., B. Raught, and N. Sonenberg, *mTOR signaling to translation.* Curr Top Microbiol Immunol, 2004. **279**: p. 169-97.
44. Avruch, J., et al., *The p70 S6 kinase integrates nutrient and growth signals to control translational capacity.* Prog Mol Subcell Biol, 2001. **26**: p. 115-54.

Wednesday, February 11, 2004 15:16:41

P
C
0
4
0
9
2
4